<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Reported-in-Senate" dms-id="A1" public-private="public" slc-id="S1-SIL25488-Y9V-6W-8DH"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1095 RS: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-04-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><calendar>Calendar No. 45</calendar><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 1095</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250324">March 24, 2025</action-date><action-desc><sponsor name-id="S311">Ms. Klobuchar</sponsor> (for herself, <cosponsor name-id="S153">Mr. Grassley</cosponsor>, <cosponsor name-id="S253">Mr. Durbin</cosponsor>, <cosponsor name-id="S341">Mr. Blumenthal</cosponsor>, <cosponsor name-id="S355">Mr. Cruz</cosponsor>, <cosponsor name-id="S422">Mr. Welch</cosponsor>, and <cosponsor name-id="S370">Mr. Booker</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name></action-desc></action><action stage="Reported-in-Senate"><action-date date="20250410">April 10, 2025</action-date><action-desc>Reported by <sponsor name-id="S153">Mr. Grassley</sponsor>, without amendment</action-desc></action><legis-type>A BILL</legis-type><official-title>To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" changed="not-changed" id="idb2d106ed-3d6d-4287-8953-4e99c8478ea7"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act</short-title></quote> or the <quote><short-title>Stop STALLING Act</short-title></quote>.</text></section><section changed="not-changed" id="idae75ed91-10d0-4f13-aff8-89121091324e"><enum>2.</enum><header>Federal Trade Commission enforcement against sham petitions</header><subsection id="id7ce6a82b-ef70-44fe-910a-f8e8d219a08f" changed="not-changed"><enum>(a)</enum><header>Definitions</header><text>In this section:</text><paragraph id="id03d189ce-8326-46f0-a9c5-38b20a29a226" changed="not-changed"><enum>(1)</enum><header>Commission</header><text>The term <term>Commission</term> means the Federal Trade Commission.</text></paragraph><paragraph id="id9971cdaa-c80e-402f-9c0a-cc7af0b2aadd" changed="not-changed"><enum>(2)</enum><header>Covered application</header><text>The term <term>covered application</term> means an application filed pursuant to subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>).</text></paragraph><paragraph id="id0d30e0bb-9007-4a1a-8faf-840ee9081ad0" changed="not-changed"><enum>(3)</enum><header>Covered petition</header><text>The term <term>covered petition</term> means a petition, or a supplement to a petition, filed under section 505(q) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(q)</external-xref>).</text></paragraph><paragraph id="id7cd7b2df-eb7c-443b-ba6f-cf0072ba6951" changed="not-changed"><enum>(4)</enum><header>Person</header><text>The term <term>person</term>—</text><subparagraph id="id0b47f800-4867-4b4e-8547-ef0d466ed41e" changed="not-changed"><enum>(A)</enum><text>means an individual or entity; and</text></subparagraph><subparagraph id="idb9f95fc4-0ce1-4fd4-b9cf-07a3fb197477" changed="not-changed"><enum>(B)</enum><text>includes—</text><clause commented="no" id="id733a7e8e-d1de-4a87-ab26-3ee67a6230b1" changed="not-changed"><enum>(i)</enum><text>a successor or an assign of an entity;</text></clause><clause commented="no" id="id6af1c34f-04e0-4336-9c0a-d6e20d8a85ec" changed="not-changed"><enum>(ii)</enum><text>a joint venture, subsidiary, partnership, division, group, or affiliate controlled by an entity; and</text></clause><clause commented="no" id="id8be17ec7-76be-44c5-a59e-e5f78cfc8ef7" changed="not-changed"><enum>(iii)</enum><text>a successor or an assign of a joint venture, subsidiary, partnership, division, group, or affiliate controlled by an entity.</text></clause></subparagraph></paragraph><paragraph id="id1e77d5e2-ef1b-4abd-b975-faeb822ca59c" changed="not-changed"><enum>(5)</enum><header>Series of covered petitions</header><text>The term <term>series of covered petitions</term> means any group of more than 1 covered petition relating to the same covered application.</text></paragraph><paragraph id="id2b443ce0-149e-44c3-94ba-69c1544409c8" changed="not-changed"><enum>(6)</enum><header>Sham</header><text>The term <term>sham</term> means—</text><subparagraph commented="no" display-inline="no-display-inline" id="id88768ee294e747b48ed125a5d170e09f" changed="not-changed"><enum>(A)</enum><text display-inline="yes-display-inline">a covered petition that—</text><clause commented="no" display-inline="no-display-inline" id="idfe05f14c86c744fd9a40f181b5614c23" changed="not-changed"><enum>(i)</enum><text display-inline="yes-display-inline">is objectively baseless; and</text></clause><clause commented="no" display-inline="no-display-inline" id="id0b82cd816cf445ce94cb6766ba608bf8" changed="not-changed"><enum>(ii)</enum><text display-inline="yes-display-inline">attempts to use a governmental process, as opposed to the outcome of that process, to interfere with the business of a competitor; or</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idfce52a518b764d0b92fbcab9ad6963dd" changed="not-changed"><enum>(B)</enum><text display-inline="yes-display-inline">a series of covered petitions that attempts to use a governmental process, as opposed to the outcome of that process, to interfere with the business of a competitor.</text></subparagraph></paragraph></subsection><subsection id="idb8cb599b-cbdd-4c76-a851-6d3894047197" changed="not-changed"><enum>(b)</enum><header>Violation</header><text>A person submitting or causing the submission of a covered petition or a series of covered petitions that is a sham shall be liable for engaging in an unfair method of competition under section 5(a)(1) of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45(a)(1)</external-xref>).</text></subsection><subsection id="ide0b3511e-43e8-4d4f-b8f5-eec82d145148" changed="not-changed"><enum>(c)</enum><header>Civil action</header><paragraph id="idaf7e353c-c0b0-4919-9c01-1a25a6832421" changed="not-changed"><enum>(1)</enum><header>In general</header><text>If the Commission has reason to believe that the submission of a covered petition or a series of covered petitions constitutes a violation of section 5(a)(1) of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45(a)(1)</external-xref>), the Commission may commence a civil action to recover a civil penalty and seek other appropriate relief in a district court of the United States against any person that submitted or caused to be submitted such covered petition or such series of covered petitions.</text></paragraph><paragraph id="ida993810c-4bf3-4a0a-9cc3-160895525089" changed="not-changed"><enum>(2)</enum><header>Presumption</header><text>In a civil action under paragraph (1), a covered petition shall be presumed to be part of a series of covered petitions that is a sham under subsection (b) of this section if—</text><subparagraph id="id2c62d872-73ef-4d55-a52c-ec8c8b47615e" changed="not-changed"><enum>(A)</enum><text>the Secretary of Health and Human Services—</text><clause id="id47b7d411-57ea-4a8b-9cfc-2b5528e4d768" changed="not-changed"><enum>(i)</enum><text>has determined that the covered petition was submitted with the primary purpose of delaying the approval of a covered application; and</text></clause><clause id="id2d3fc214-9c7d-4a00-8851-8d8f5e3f3d23" changed="not-changed"><enum>(ii)</enum><text>has referred such determination to the Commission in writing, including a reasoned basis for the determination; and</text></clause></subparagraph><subparagraph id="id756ba43b-d769-418f-b9ec-c86a412caa84" changed="not-changed"><enum>(B)</enum><text>the covered petition was part of a series of covered petitions.</text></subparagraph></paragraph><paragraph id="id5765e36c-56c7-45c4-a690-5311d7259a6c" changed="not-changed"><enum>(3)</enum><header>Exception</header><text>The presumption in paragraph (2) shall not apply if the defendant establishes, by a preponderance of the evidence, that the series of covered petitions that includes the covered petition referred to the Commission by the Secretary of Health and Human Services is not a sham.</text></paragraph><paragraph id="id0ba33467-59fc-4df0-b577-bac32e793ea9" changed="not-changed"><enum>(4)</enum><header>Civil penalty</header><text>In an action under paragraph (1), any person that has been found liable for a violation of section 5(a)(1) of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45(a)(1)</external-xref>) shall be subject to a civil penalty for each violation of not more than the greater of—</text><subparagraph id="id131f72a7-3451-4e8b-b4d8-447e86113f47" changed="not-changed"><enum>(A)</enum><text>any revenue earned from the sale by such person of any drug product, referenced in a covered application that was the subject of a covered petition or a series of covered petitions that is a sham, during the period during which the covered petition or series of covered petitions was under review by the Secretary of Health and Human Services; or</text></subparagraph><subparagraph id="idfcb0eea4-fcb9-4485-8f0d-0b81205b4936" changed="not-changed"><enum>(B)</enum><text>$50,000 for each calendar day that each covered petition that is a sham or that was part of a series of covered petitions that is a sham was under review by the Secretary of Health and Human Services.</text></subparagraph></paragraph><paragraph id="id23556665760b496b9d700f8d0ef16c94" changed="not-changed"><enum>(5)</enum><header>Review of referral</header><text>No referral by the Secretary of Health and Human Services under paragraph (2)(A) shall be subject to judicial review, except as a third-party claim asserted by the defendant under section 706(2)(A) of title 5, United States Code, against the Secretary of Health and Human Services or the Department of Health and Human Services, as part of a civil action commenced under paragraph (1). </text></paragraph><paragraph id="ideb6500ce-a26f-4169-9bcd-95da658b3471" changed="not-changed"><enum>(6)</enum><header>Antitrust laws</header><text>Nothing in this section shall modify, impair, limit, or supersede the applicability of the antitrust laws, as defined in subsection (a) of the first section of the Clayton Act (<external-xref legal-doc="usc" parsable-cite="usc/15/12">15 U.S.C. 12</external-xref>), and of section 5 of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45</external-xref>) to the extent that it applies to unfair methods of competition.</text></paragraph><paragraph id="idd8ab180f-ff35-4e8b-b7cd-2faea1da612d" changed="not-changed"><enum>(7)</enum><header>Rule of construction</header><text>The civil penalty provided in this subsection is in addition to, and not in lieu of, any other remedies provided by Federal law, including under section 16 of the Clayton Act (<external-xref legal-doc="usc" parsable-cite="usc/15/26">15 U.S.C. 26</external-xref>) or under section 13(b) of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/53">15 U.S.C. 53(b)</external-xref>). </text></paragraph></subsection><subsection id="id0539596b-0134-4bea-87ba-fb1feb316a04" changed="not-changed"><enum>(d)</enum><header>Applicability</header><text>This section shall apply to any covered petition submitted on or after the date of enactment of this Act.</text></subsection><subsection id="id1C26F4E9265947EA994CA43917ABFD62" changed="not-changed"><enum>(e)</enum><header>Rule of construction</header><text>Nothing in this Act shall be construed to limit any authority of the Commission under any other provision of law.</text></subsection></section><section changed="not-changed" id="id684e103e-f983-4c97-a0be-09f799f82ff3"><enum>3.</enum><header>Severability</header><text display-inline="no-display-inline">If any provision of this Act or the application of such provision to any person or circumstance is held to be unconstitutional, the remainder of this Act and the application of the provisions of such Act to any person or circumstance shall not be affected.</text></section></legis-body><endorsement><action-date date="20250410">April 10, 2025</action-date><action-desc>Reported without amendment</action-desc></endorsement></bill> 

